Drug interaction of ningetinib and gefitinib involving CYP1A1 and efflux transporters in non‐small cell lung cancer patients-Reference-Cited by-同舟云学术

Drug interaction of ningetinib and gefitinib involving CYP1A1 and efflux transporters in non‐small cell lung cancer patients

Published:2020-11-15 Issue:4 Volume:87 Page:2098-2110
ISSN:0306-5251
Container-title:British Journal of Clinical Pharmacology
language:en
Short-container-title:Br J Clin Pharmacol

Author:

Liu Lu¹²^ORCID,Wang Qian³^ORCID,Xie Cen¹²,Xi Ning³^ORCID,Guo Zitao²,Li Ming³^ORCID,Hou Xiangyu¹²,Xie Ningjie¹²^ORCID,Sun Mingming³^ORCID,Li Jing³^ORCID,Chen Xiaoyan¹²^ORCID

Affiliation:

1. University of Chinese Academy of Sciences No. 19A Yuquan Road Beijing 100049 China

2. Shanghai Institute of Materia Medica, Chinese Academy of Sciences 501 Haike Road Shanghai 201203 China

3. State Key Laboratory of Anti‐Infective Drug Development (No. 2015DQ780357), Sunshine Lake Pharma Co. Ltd Dongguan 523871 P. R. China

Funder

Guangdong Province Introduction of Innovative R&D Team

Publisher

Wiley

Subject

Pharmacology (medical),Pharmacology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/bcp.14621

Reference24 articles.

1. Targeting emerging molecular alterations in the treatment of non-small cell lung cancer: current challenges and the way forward

2. Targeted therapies for advanced non-small cell lung cancer

3. Multi-Targeted Anticancer Agents

4. Combination therapy of apatinib with icotinib for primary acquired icotinib resistance in patients with advanced pulmonary adenocarcinoma with EGFR mutation

5. Dovitinib and erlotinib in patients with metastatic non-small cell lung cancer: A drug–drug interaction

Cited by 12 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. In Vitro Assessment of Inhibitory Effects of Kinase Inhibitors on CYP2C9, 3A and 1A2: Prediction of Drug-Drug Interaction Risk with Warfarin and Direct Oral Anticoagulants;European Journal of Pharmaceutical Sciences;2024-08

2. Ningetinib, a novel FLT3 inhibitor, overcomes secondary drug resistance in acute myeloid leukemia;Cell Communication and Signaling;2024-07-08

3. Redefining the significance of quinoline containing compounds as potent VEGFR-2 inhibitors for cancer therapy;Medicinal Chemistry Research;2024-06-27

4. Challenges and opportunities of developing small-molecule therapies for age-related macular degeneration;Archives of Pharmacal Research;2024-06

5. Identification of a 2‐phenylthiazole derivative acetylcholinesterase modulator with in vitro antitumor activity in breast cancer cells;Chemical Biology & Drug Design;2023-11-27